# The Rising Power of Electrochemotherapy in Musculoskeletal Oncology

**Authors:** Nicolas Papalexis, Giuliano Peta, Simone Quarchioni, Laura Campanacci, Alessandro Gasbarrini, Giuseppe Tedesco, Michela Carta, Maddalena Di Carlo, Marco Miceli, Giancarlo Facchini

PMC · DOI: 10.3390/curroncol33030143 · 2026-02-28

## TL;DR

Electrochemotherapy is gaining popularity in treating musculoskeletal tumors by improving chemotherapy effectiveness through cell membrane permeability.

## Contribution

This review highlights the expanding use of electrochemotherapy in musculoskeletal oncology and summarizes its efficacy and safety.

## Key findings

- Electrochemotherapy is effective for bone and soft tissue malignancies.
- Advancements in electrode design and imaging have improved treatment outcomes.
- Initial studies show promise in treating desmoid fibromatosis and vascular malformations.

## Abstract

Electrochemotherapy is a minimally invasive technique that enhances the effectiveness of chemotherapy by increasing cell membrane permeability through reversible electroporation. It is now on the rise in the treatment of various lesions, including musculoskeletal tumors, bone and soft tissue malignancies, and vascular malformations. This review summarizes current literature on its applications in musculoskeletal conditions, highlighting evidence on efficacy, safety, and recurrence rates.

Electrochemotherapy is a minimally invasive treatment based on the principle of reversible electroporation of target cells in pathologic tissues in order to increase the local effect of chemotherapeutic agents. The mechanism of action relies on temporarily increasing cell permeability to increase the uptake of cytotoxic drugs in the intracellular space. Originally developed for the treatment of cutaneous malignancies, electrochemotherapy has significantly evolved over the past few decades, thanks to advancements in electrode design and image guidance, finding fertile ground in musculoskeletal oncological pathologies, such as bone and soft tissue tumors and different kinds of vascular malformations. Moreover, initial experiences have reported on the treatment of other soft tissue tumors such as desmoid fibromatosis. The aim of this review is to summarize the literature on the role of electrochemotherapy across a variety of musculoskeletal conditions, starting from established oncologic indications, such as metastatic bone or soft tissue tumors, to emerging evidence on primary musculoskeletal pathology, with particular attention paid to the results of the leading studies relating to the efficacy, complications, and recurrence rate.

## Linked entities

- **Diseases:** desmoid fibromatosis (MONDO:0007608)

## Full-text entities

- **Genes:** ECT (centralopathic epilepsy) [NCBI Gene 100379198] {aka BECTS}, CALR (calreticulin) [NCBI Gene 811] {aka CALR1, CRT, HEL-S-99n, RO, SSA, cC1qR}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, HMGB1 (high mobility group box 1) [NCBI Gene 3146] {aka HMG-1, HMG1, HMG3, SBP-1}
- **Diseases:** -Spinal Bone Metastases (MESH:D009362), paraplegia (MESH:D010264), fibromatosis (MESH:D005350), skeletal disease (MESH:D004194), DF (MESH:D018222), skin ulceration (MESH:D012883), AVMs (MESH:D001165), cutaneous and subcutaneous malignancies (MESH:C562393), aggressive (MESH:D010554), Tumor (MESH:D009369), Vertebral Hemangioma (MESH:D006391), spinal canal compression (MESH:D013117), bone (MESH:D001847), AVM (MESH:D001159), musculoskeletal oncological (MESH:D009140), Soft Tissue Tumors (MESH:D012983), skin hyperpigmentation (MESH:D017495), Soft Tissue Sarcomas (MESH:D012509), bleeding (MESH:D006470), injury to (MESH:D014947), neural compression (MESH:D009408), involuntary muscle contractions (MESH:C536214), melanoma (MESH:D008545), ischemia (MESH:D007511), swelling (MESH:D004487), desmoid tumor (MESH:C535944), neurologic impairment (MESH:D009422), head and neck AVMs (MESH:D006258), radicular hypoesthesia (MESH:D006987), seizures (MESH:D012640), oncologic (MESH:D000072716), vascular anomalies (MESH:D020785), back pain (MESH:D001416), fracture (MESH:D050723), femoral, humeral (MESH:D006810), neurological complications (MESH:D002493), allergy (MESH:D004342), congenital anomalies (MESH:D000013), venous malformations (MESH:C563977), vascular lesions (MESH:D014652), skin necrosis (MESH:D012871), osteolytic lesion (MESH:D030981), colon adenocarcinoma (MESH:D003110), malformations (MESH:C564254), Breast, kidney, and lung cancers (MESH:D001943), cytotoxic (MESH:D064420), Pain (MESH:D010146), embolization (MESH:D004617), Vascular Malformations (MESH:D054079), necrosis (MESH:D009336)
- **Chemicals:** polidocanol (MESH:D000077423), BEST (-), reactive oxygen species (MESH:D017382), Bleomycin (MESH:D001761), cisplatin (MESH:D002945), Pazopanib (MESH:C516667), ATP (MESH:D000255)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Canis lupus familiaris (dog, subspecies) [taxon 9615], Homo sapiens (human, species) [taxon 9606]

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13025487/full.md

---
Source: https://tomesphere.com/paper/PMC13025487